Pinealon
EDR peptide, Glu-Asp-Arg, EDR tripeptide, Pinealon-6
The Ground Truth Score
four plain questions, never one numberRussian lab data is real but comes from one research group, and no controlled human trial exists outside Eastern Europe. The sleep effects Huberman reports are anecdote, not evidence.
Bottom line
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, with a plausible neuroprotective mechanism supported by cell-culture and rodent studies, one small uncontrolled Russian human trial, and zero independent Western replication. That puts it squarely in the 'interesting but unverified' tier.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓100-300 mcg SubQ once daily, evening, in 10-20 day cycles (community reported); no established human protocol
Reported, not prescribed. Verify your vial and your math.
The gist
- People use it for REM sleep and brain aging, mostly off the back of Huberman's n=1 report where he co-administered glycine, so attribution is impossible.
- The preclinical science is real but comes entirely from one Russian lab, and the only PubMed-indexed human study found inhibition of blood stem cell production, which nobody in the community talks about.
- Oral bioavailability is expected to be near zero for a tripeptide; the Russian clinical protocol used oral dosing anyway, which means the route-of-administration question alone is still completely open.
First documented human use
No controlled human trial has been completed in the Western peer-reviewed literature. A Russian clinical report described 72 patients with cerebral asthenia after cranial trauma (ages 30-74) receiving oral Pinealon at 0.2 mg twice daily for 20-30 days alongside standard rehabilitation, published as a chapter in Khavinson et al., 'Peptides in the Epigenetic Control of Ageing.' The study has not been independently replicated and is not indexed in PubMed. The primary source is a book chapter from the Khavinson group, not a publicly accessible peer-reviewed journal article.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Supports pineal gland function and endogenous melatonin production
- Protects neurons against oxidative stress and age-related decline
- May improve memory and cognitive performance after brain injury
- Promotes restorative REM sleep when used intermittently
- May slow biological markers of brain aging via epigenetic regulation
The data behind each bullet
What actually backs it
Pinealon reduces reactive oxygen species in neuronal cell cultures
In vitro study in cerebellar granule cells, neutrophils, and PC12 cells showed dose-dependent ROS suppression and delayed ERK1/2 activation under oxidative stress conditions. Cell-culture finding, not a human trial. Single research group.
Khavinson et al. 2011, Rejuvenation Research, PMID 21978084 ↗Pinealon restores neuronal dendritic spine density in Alzheimer's disease cell models
Mouse hippocampal neuron cultures exposed to amyloid-induced synaptotoxicity showed 71% increase in mushroom spine number at 200 ng/ml EDR. In vitro only. Authors explicitly recommended further experimental study before clinical application.
Kraskovskaya et al. 2017, Bull Exp Biol Med, PMID 28853087 ↗Pinealon improves offspring cognition when given to pregnant rats exposed to high homocysteine
Rat model: pregnant animals on high-methionine diet received EDR; offspring showed improved spatial orientation, learning, and reduced cerebellar neuron ROS. Rodent model of prenatal metabolic stress. Not translatable to healthy adult humans.
Arutjunyan et al. 2012, Int J Clin Exp Med, PMID 22567179 ↗Pinealon improves memory in patients recovering from traumatic brain injury
Russian clinical report, approximately 72 patients with cerebral asthenia after cranial trauma (ages 30-74), 0.2 mg oral twice daily for 20-30 days alongside standard rehabilitation. Reported improvement in memory, emotional stability, and reduced headache duration. Not a randomized controlled trial. No placebo arm. The primary source is a book chapter by Khavinson et al. published through the St. Petersburg Institute of Bioregulation and Gerontology. This source is not independently accessible, not PubMed-indexed, and not reproducible by independent researchers. The vendor/aggregator page below is a secondary summary only and does not constitute a verifiable citation. The original Russian-language book chapter is not publicly accessible and this claim cannot be independently verified from public sources.
Khavinson et al., 'Peptides in the Epigenetic Control of Ageing.' Primary source not publicly accessible, unverified. Secondary summary only via aggregator sites (no PMID, no DOI, no independent journal publication). ↗Pinealon interacts with DNA to epigenetically regulate neuroprotective gene expression
Molecular docking and ion-interaction models show Glu-Asp-Arg partly penetrates the major groove of DNA, potentially affecting guanine N7/O6 base atoms. HeLa cell fluorescence confirms cellular penetration. This is a proposed mechanism only, not proven to cause specific gene expression changes in human neurons in vivo.
Khavinson et al. 2019, role of ions in EDR-DNA interaction, PMID 30762356 ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
ASSUMED (theoretical, not proven in vivo in humans). Pinealon (Glu-Asp-Arg) is proposed to act as a short-peptide epigenetic regulator: the tripeptide penetrates cell nuclei (confirmed in HeLa cell fluorescence studies) and is modeled to interact with guanine base atoms in DNA promoter regions. This is proposed to upregulate genes involved in neuroprotection, antioxidant defense (via MAPK/ERK pathway modulation), and apoptosis suppression. In pineal gland tissue specifically, it is theorized to activate CREB transcription factor to upregulate melatonin synthesis genes (AANAT). All of this is mechanistically plausible and partially supported by cell-culture data, but has not been demonstrated in human tissue in vivo.
Dosing & handling
What users and clinicians report
Community-reported protocols vary significantly. Injectable: 100-300 mcg subcutaneous, daily or several nights per week, evening dosing. Oral: 0.2 mg twice daily for 20-30 day courses (the Russian clinical protocol). Huberman describes intermittent pulsed use (not nightly). Course lengths of 20-30 days with 3-6 month gaps are most commonly cited.
These are community-reported protocols, not prescribed doses. Oral bioavailability for a tripeptide is expected to be very low (gastric peptidase degradation). No human pharmacokinetic study exists to confirm what dose actually reaches the CNS. The biggest dosing risk is the complete absence of dose-safety data in healthy adults for any route. The Russian 0.2 mg oral dose is from a single rehabilitation study, not a healthy-adult optimization protocol.
Timing & food
Community consensus favors evening administration (1-2 hours before sleep) to align with the proposed melatonin and pineal gland mechanism. Some protocols use morning dosing for the cognitive claims. The Russian clinical protocol used twice-daily oral dosing without timing specificity in available summaries. No pharmacokinetic basis for timing guidance exists.
Half-life
Unknown. No human or animal pharmacokinetic study exists for Pinealon. Theoretical estimates based on short tripeptide structure suggest plasma half-life of minutes to 1-2 hours. Subcutaneous absorption timeline is uncharacterized. Oral bioavailability is expected to be very low (gastric acid and peptidase degradation of tripeptides) but has not been measured.
Reconstitution sensitivity
Standard peptide reconstitution applies: bacteriostatic water, store refrigerated at 2-8C after reconstitution. Stable approximately 30 days reconstituted. Protect from light. Avoid repeated freeze-thaw. No Pinealon-specific reconstitution sensitivity data exists.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Growing but still thin. Huberman's public endorsement in 2023-2024 seeded a wave of community reports, but the total user base is small compared to compounds like BPC-157 or TB-500. Most English-language discussion is recent and Huberman-catalyzed.
Consistency
Reports on sleep and vivid dreams are reasonably consistent. Cognitive effects are inconsistent and harder to attribute. The sleep signal is the strongest community thread.
Source credibility
Low-to-moderate. Almost all community reports involve co-administration with glycine (which has its own strong sleep data), Epitalon, or TRT. Independent single-compound Pinealon reports are rare. Huberman's self-report is the highest-credibility anecdote but it is still an n=1 with a confound (glycine).
- Anecdote: the most consistent report is unusually vivid or intense dreams, sometimes described as cinematic. This appears in both the Russian clinical literature (as a minor side effect) and Western community reports.
- Anecdote: users report improved sleep depth and subjective morning alertness within 1-2 weeks of starting. Almost universally co-administered with glycine, so attribution is unclear.
- Anecdote: some users describe noticeable improvements in focus and word recall during course periods, most often in the 40+ demographic. These reports are impressionistic and not tracked against any baseline.
- Anecdote: Huberman publicly described his REM sleep roughly doubling over 4-6 months of pulsed use (not nightly), tracked on an Eight Sleep mattress. He was taking glycine concurrently. This is the single highest-visibility self-report and has driven most Western interest.
Placebo risk, High
Sleep quality and cognitive function are highly subjective and highly susceptible to expectation effects, especially when used by biohackers who are actively tracking, optimizing, and paying attention to their metrics. Vivid dreams and any perceptible sleep sensation provide a concrete 'signal' that reinforces belief in the compound working. No objective biomarker (like GH secretion for GHRP-2) exists for the primary claimed benefits.
Risk panel
What could go wrong
Adverse events
Minimal adverse events reported in the Russian clinical and preclinical literature. Injection-site reactions (redness, mild swelling) are the most commonly listed. Some users report very vivid or intense dreams, transient mild headache, and minor fatigue. Small blood sugar drops noted in a small number of anecdotal reports. No serious adverse events documented in available published material. One PubMed-indexed human study (PMID 26390612, 32 patients) found significant inhibition of hemopoiesis as measured by decreased CD34+ hematopoietic progenitor cells. That study's authors explicitly called for additional safety studies before broader use.
Theoretical concerns
Pinealon targets the central nervous system and is claimed to influence epigenetic gene regulation. Long-term consequences of exogenous epigenetic modulation in healthy adults are completely unstudied. Any peptide with CNS activity in a poorly characterized population carries unknown risk. Melatonin-pathway modulation could theoretically disrupt circadian regulation if used chronically and incorrectly timed. The hemopoiesis inhibition signal from the only PubMed-indexed human study adds an unresolved safety question that has not been followed up in any published study.
Contraindications
Pregnancy and lactation (by convention, not proven risk). Active seizure disorders or a history of neurological conditions warrant caution given CNS targeting. Under 18. Allergy to any component. Given the hemopoiesis inhibition signal found in PMID 26390612, individuals with blood disorders or on chemotherapy or immunosuppressive agents should exercise additional caution.
Honest unknowns
No pharmacokinetic data (half-life, bioavailability, distribution, clearance) exists from formal human or animal studies. Oral bioavailability is theoretically very low for a tripeptide but has not been measured. Long-term effect on endogenous pineal or melatonin regulation is unknown. Interactions with TRT, GLP-1 agonists, melatonin supplements, or other peptides are unstudied. The clinical significance of the hemopoiesis inhibition signal from the 2015 human study is unknown, as no follow-up study has been published.
Confound watch
The biggest confound in community reports is co-administration with glycine (3-5g oral), which independently improves sleep quality and REM in controlled trials. Huberman's reported REM doubling was with Pinealon plus glycine, so attribution is impossible. Users also frequently stack Pinealon with Epitalon (another Khavinson pineal bioregulator), making cross-compound attribution impossible. TRT independently improves sleep architecture and cognitive function. The wellness community stacks these together and attributes outcomes to Pinealon by default.
History
Discovery → first use → status
- 1970s-1980sVladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology begin developing short peptide bioregulators derived from organ extracts, originally for Soviet military and cosmonaut health programs. Cortexin (polypeptide brain extract) precedes the synthetic tripeptide era.
- 2000s-2010sThe EDR tripeptide (Glu-Asp-Arg) is isolated and synthesized as a defined compound from the broader Cortexin bioregulator research. Khavinson group publishes foundational in vitro and rodent neuroprotection studies establishing the 'pinealon' name and proposed mechanism.
- 2011-2017Core preclinical evidence published: ROS suppression in cerebellar cells (2011, PMID 21978084), prenatal rat neuroprotection (2012, PMID 22567179), dendritic spine restoration in Alzheimer's cell model (2017, PMID 28853087). All Khavinson-affiliated. No independent replication.
- 2015The only PubMed-indexed human study that includes Pinealon as one of the tested compounds is published in Advances in Gerontology (PMID 26390612). The 32-patient uncontrolled observational study in elderly patients with polymorbidity and organic brain syndrome found that Pinealon had significant anabolic effects and slowed aging by biological age indicators, but also found significant inhibition of hemopoiesis (decreased CD34+ hematopoietic progenitor cells in blood). The authors called for additional safety studies. This is not a healthy-adult optimization study. Vesugen, not Pinealon, showed the stronger geroprophylactic effect in this study.
- 2023-2026Andrew Huberman publicly reports using Pinealon intermittently (pulsed, not nightly) for REM sleep, describing roughly doubled REM hours tracked over 4-6 months. Popularizes the compound in Western biohacking communities. No change to the underlying evidence grade.
Verification
The COA standard, applied
Grade adversarially re-reviewed 2026-06-21 and downgraded to reflect the absence of formal human safety/efficacy data. Citation fixes applied 2026-06-22: TBI human study citation relabeled as 'primary source not publicly accessible, unverified' and peptide-db.com vendor link retained only as secondary aggregator summary, not a verifiable citation anchor. PMID 26390612 (the only PubMed-indexed human study including Pinealon) added to verification sources and history; its hemopoiesis inhibition signal added to risk.adverseEvents, risk.theoretical, risk.contraindications, and risk.unknowns.
The full verification standard →Sources
Where this comes from
- Khavinson et al. 2011 - Pinealon increases cell viability by suppression of free radical levels (PMID 21978084) ↗· Core in vitro neuroprotection paper. Cerebellar granule cells, neutrophils, PC12 cells. Dose-dependent ROS suppression and ERK modulation. Real study but preclinical only.
- Kraskovskaya et al. 2017 - Tripeptides restore neuronal spines in Alzheimer's disease model (PMID 28853087) ↗· In vitro mouse hippocampal neuron study. EDR (Pinealon) at 200 ng/ml restored mushroom spine count by 71% under amyloid synaptotoxicity. Authors called for further study, not clinical use.
- Arutjunyan et al. 2012 - Pinealon protects rat offspring from prenatal hyperhomocysteinemia (PMID 22567179) ↗· Rodent model, not human. Establishes the neuroprotective and cognitive claims at the animal level. The most cited animal study.
- Khavinson et al. 2019 - Role of mono and divalent ions in EDR-DNA interaction (PMID 30762356) ↗· Molecular mechanism paper. Models how Glu-Asp-Arg interacts with DNA base atoms. Underlies the epigenetic regulatory claim but is computational, not a human gene expression study.
- Khokhlova et al. 2015 - Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome (PMID 26390612, Advances in Gerontology) ↗· The only PubMed-indexed human study that includes Pinealon. 32 patients (18 men, 12 women, ages 41-83), uncontrolled observational design, not a healthy-adult trial. Found anabolic effects and slowed biological aging indicators but also found significant inhibition of hemopoiesis (decreased CD34+ progenitor cells). Authors called for additional safety studies. Vesugen showed stronger effect than Pinealon in this study.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.